Chloroquine
Small molecule targets ATM, TNF via activation / inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ARALEN | — | 1949-10-31 | fda.gov ↗ |
Trials 104 · started per year
Also used as a comparator or background therapy in 77 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02996695 Background | Apr 2017 → Jun 2018 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03070470 Comparator | Mar → Jun 2017 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02773979 Comparator | Sep 2016 → Jan 2018 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00969306 Comparator | Sep 2013 → Jun 2016 | small cell lung carcinoma | Maastricht Radiation Oncology | Terminated | No outcome recorded |
| Phase 1 | NCT01205178 Comparator | Jul 2009 → Apr 2013 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00871156 Comparator | Mar → Aug 2009 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00844207 Comparator | Feb → Apr 2009 | malaria | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00323375 Comparator | Aug 1999 → Jun 2005 | malaria | Tulane University Health Sciences Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00849602 Comparator | Feb → May 2008 | dengue disease | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07430592 Comparator | Jul 2026 → Nov 2028 expected | Plasmodium vivax malaria | R. Kiplin Guy | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03503058 Comparator | May 2022 → Feb 2024 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04342650 Comparator | Apr → May 2020 | COVID-19, severe acute respiratory syndrome | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Completed | No outcome recorded |
| Phase 2 | NCT04323527 Comparator | Mar → May 2020 | COVID-19, severe acute respiratory syndrome | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Completed | No outcome recorded |
| Phase 2 | NCT04428268 Background | Mar → Jun 2020 | pneumonia | Hospital Universitario Dr. Jose E. Gonzalez | Withdrawn | No outcome recorded |
| Phase 2 | NCT03278808 Comparator | Sep 2018 → Dec 2019 | malaria | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded |
| Phase 2 | NCT03529396 Comparator | Jul 2018 → Dec 2022 | G6PD deficiency, Plasmodium vivax malaria | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Completed | No outcome recorded |
| Phase 2 | NCT02563496 Background | Feb 2017 → Dec 2019 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01376167 Background | Apr 2014 → Nov 2016 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01946880 Background | Nov 2013 → Jul 2019 | systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00811096 Comparator | Nov 2008 → Jan 2009 | Plasmodium vivax malaria | Walter Reed Army Institute of Research (WRAIR) | Completed | No outcome recorded |
| Phase 2 | NCT00455325 Comparator | Sep 2004 → Jun 2010 | hyperlipidemia, hypertensive disorder, metabolic syndrome X, obesity disorder +1 | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01290601 Comparator | Sep 2003 → Jan 2005 | Plasmodium vivax malaria | U.S. Army Medical Research and Development Command | Terminated | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT05232227 Background | Jan → Jun 2023 | Plasmodium vivax malaria | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04395170 Background | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
| Phase 2/3 | NCT04434248 Comparator | Apr → Jul 2020 | COVID-19 | Chromis LLC | Unknown | No outcome recorded |
| Phase 2/3 | NCT04351295 Comparator | Apr → Sep 2020 | COVID-19 | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04475120 Comparator | Apr → Jul 2020 | COVID-19 | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 2/3 | NCT01718054 Comparator | Aug 2012 → Sep 2016 | sickle cell disease | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT00084240 Background | Mar 2004 → Apr 2005 | Plasmodium falciparum malaria | Pfizer | Terminated | No outcome recorded |
| Phase 2/3 | NCT00074841 Background | Sep 2003 → Jan 2005 | Plasmodium falciparum malaria | Pfizer | Completed | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT06666491 Background | Nov 2024 → May 2026 overdue | Plasmodium vivax malaria | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT04501783 Comparator | May → Jul 2020 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT04341727 Comparator | Apr 2020 → Apr 2021 | COVID-19 | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 3 | NCT03208907 Comparator | Jul 2018 → Jul 2021 | Plasmodium vivax malaria | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Completed | No outcome recorded |
| Phase 3 | NCT02873936 Background | Jul 2016 → Mar 2018 | rheumatoid arthritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01785979 Comparator | Jan 2016 → Feb 2017 | anemia, chronic congestive splenomegaly, malaria | Lihir Medical Centre | Withdrawn | No outcome recorded |
| Phase 3 | NCT02216123 Background | Apr 2015 → Nov 2016 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02348788 Comparator | Jan 2015 → Dec 2017 | Plasmodium vivax malaria | Menzies School of Health Research | Unknown | No outcome recorded |
| Phase 3 | NCT02001012 Comparator | Jan 2014 → Jan 2015 | — | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 3 | NCT01941095 Background | Nov 2013 → Jul 2016 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01708876 Comparator | Oct 2012 → Dec 2014 | — | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 3 | NCT01640574 Comparator | Feb 2012 → Jul 2015 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT01378286 Comparator | Jan 2012 → Jun 2013 | malaria | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01256736 Background | Mar 2010 → Dec 2011 | rheumatoid arthritis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01136850 Comparator | Nov 2009 → Dec 2012 | anemia, malaria, sexually transmitted disease | University of Melbourne | Completed | No outcome recorded |
| Phase 3 | NCT01211834 Comparator | Oct 2009 → Oct 2010 | rheumatoid arthritis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00531817 Background | Oct 2007 → Jun 2009 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04368910 Comparator | Sep 2007 → Oct 2010 | malaria | Medicines for Malaria Venture | Terminated | No outcome recorded |
| Phase 3 | NCT00682578 Comparator | Jul 2007 → Feb 2010 | Plasmodium falciparum malaria, Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00521924 Comparator | Jun 2007 → Apr 2008 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00440999 Comparator | Mar 2007 → Apr 2008 | Plasmodium vivax malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 3 | NCT00720798 Background | Sep 2005 → Apr 2013 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00730366 Comparator | Mar 2004 → Oct 2006 | Plasmodium falciparum malaria | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT04704999 Comparator | Jul 2024 → Oct 2027 expected | Plasmodium vivax malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 4 | NCT04351191 Comparator | Apr → Aug 2020 | COVID-19 | Government of Punjab, Specialized Healthcare and Medical Education Department | Terminated | No outcome recorded |
| Phase 4 | NCT04362332 Comparator | Apr → Jun 2020 | COVID-19 | UMC Utrecht | Terminated | No outcome recorded |
| Phase 4 | NCT04346667 Comparator | Apr → Aug 2020 | COVID-19 | Government of Punjab, Specialized Healthcare and Medical Education Department | Terminated | No outcome recorded |
| Phase 4 | NCT04286503 Comparator | Feb 2020 → Feb 2021 | COVID-19 | Beijing YouAn Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03449758 Background | Mar 2018 → Jul 2019 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02876549 Background | Sep 2016 → Nov 2018 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02192944 Comparator | Jul 2014 → Sep 2015 | — | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT01887821 Comparator | Feb 2013 → Jun 2015 | Plasmodium vivax malaria | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT01662700 Comparator | Oct 2012 → Dec 2014 | Plasmodium vivax malaria | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT01107145 Comparator | Feb 2011 → Jan 2012 | Plasmodium vivax malaria | Centers for Disease Control and Prevention | Terminated | No outcome recorded |
| Phase 4 | NCT00964691 Comparator | Aug 2009 → Aug 2010 | malaria | Ministry of Health and Medical Services, Solomon Islands | Terminated | No outcome recorded |
| Phase 4 | NCT02143934 Comparator | Aug 2009 → May 2010 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Papua New Guinea Institute of Medical Research | Completed | No outcome recorded |
| Phase 4 | NCT01178021 Comparator | Aug 2009 → Feb 2014 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02463331 Comparator | May 2003 → Jun 2015 | autoimmune hepatitis | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01980745 Comparator | Feb 2002 → Nov 2013 | autoimmune hepatitis | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01019408 Comparator | Nov 1993 → Jan 1995 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07533136 Comparator | May 2026 → Oct 2028 expected | Plasmodium vivax malaria | Walter Reed Army Institute of Research (WRAIR) | Not yet recruiting | No outcome recorded |
| — | NCT02098590 Background | Oct 2014 → Nov 2015 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT02080026 Background | Jun 2014 → Jul 2015 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01422954 Comparator | Jan → Dec 2012 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01236612 Background | Apr 2011 → Jun 2012 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01218893 Background | Apr 2011 → Jan 2012 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00473837 Comparator | Jul 2007 → Feb 2009 | malaria | Medical Research Council Unit, The Gambia | Completed | No outcome recorded |
Evidence & citations 39 cited values
Every value below carries the sentence it was read from. 183 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chloroquine | “The fMDA regimen will include 25mg/kg chloroquine (CQ) plus a single 300mg dose of tafenoquine (TQ) for individuals age ≥16 years, and 25mg/kg of CQ plus 7 days of 0.5mg/kg/day...” PMID 40321759 ↗ Apr 2025175“csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗ “In animals, activation of the protein ataxia telangiectasia mutated (ATM) using the antimalarial drug chloroquine improves features of metabolic syndrome and decreases atherosclerosis.” NCT00455325 ↗ “The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00531817 ↗ “Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00720798 ↗ “Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01211834 ↗ “Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets” NCT05232227 ↗ “Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01256736 ↗ “single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together” PMID 24687509 ↗ Mar 2014 “To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin.” NCT04395170 ↗ “umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine” NCT04501783 ↗ “a three-day course of either chloroquine (Ethiopia) or artesunate-amodiaquine (Madagascar)” NCT06923592 ↗ “Chloroquine (150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug” NCT05540470 ↗ “chloroquine (150 mg oral tablets) were administered once daily for 3 days” PMID 42114535 ↗ May 2026 “chloroquine 500 mg, 1x2/day or hydroxychloroquine cp 200 mg, 1x2/day” NCT04475120 ↗ “Chloroquine (CQ) is an old drug widely used to treat malaria.” NCT03400865 ↗ “healthy human volunteers taking chloroquine chemoprophylaxis” NCT02098590 ↗ “Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.” NCT04434248 ↗ “Chloroquine combined with Tafenoquine” NCT07430592 ↗ “Oral 250mg chloroquine tablets” NCT04772846 ↗ “Chloroquine” NCT00871156 ↗ |
| Known as | [3H]-CHLOROQUINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | A-CQ 100 | “Chloroquine, A-CQ 100” NCT00969306 ↗ |
| Known as | Aralen | “6,000 tablets of chloroquine 150 mg (Aralen) and 6,000 identical tablets of placebo” NCT00224978 ↗ |
| Known as | Aralen GENERIC NAME(S): Chloroquine Phosphate | “Aralen GENERIC NAME(S): Chloroquine Phosphate” NCT04341727 ↗ |
| Known as | Aralen hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Arechin | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Avloclor | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Chloroquine [3H] | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Chloroquine diphosphate | “Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).” NCT04342650 ↗2“Chloroquine diphosphate is an antimalarial drug that has been used for the treatment of rheumatological diseases for at the least five decades.” NCT02463331 ↗ |
| Known as | Chloroquine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | CHLOROQUINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Chloroquine phosphate | “tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base)” NCT02216123 ↗6“Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg” NCT04341727 ↗ “UNIKINON (Chloroquine phosphate) 200mg tablets” NCT04344951 ↗ |
| Known as | Chloroquine phosphate GPO | “Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).” NCT01546961 ↗ |
| Known as | Chloroquine Sulfate | “Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days” NCT02118090 ↗1“Drug: Chloroquine Sulfate” NCT04341727 ↗ |
| Known as | Chloroquine sulfate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Chloroquine sulphate | “Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg” NCT02698748 ↗ |
| Known as | Chloroquini phosphas | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Chloroquini sulfas | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Ciplaquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Cloroquina | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | CPS-immunization | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03813108 ↗ |
| Known as | Lariago | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Malaquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Malarivon | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Melubrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Meriquine | “Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg” NCT02698748 ↗ |
| Known as | Nivaquine | “standard doses of Nivaquine® (Chloroquine) with standard doses of Rimstar® (4-drug anti-TB therapy)” NCT05443178 ↗ |
| Known as | NSC-14050 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | NSC-187208 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | NSC-292296 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | Resochin | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | SN-7618 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Known as | UNIKINON | “UNIKINON (Chloroquine phosphate) 200mg tablets” NCT04344951 ↗ |
| Known as | WR-1522 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76 ↗ |
| Action | Inhibit | “chloroquine provides a significant inhibition on the replication of the Chikungunya virus.” NCT00391313 ↗ |
| Modality | Small molecule | “Chloroquine is a drug of the group of 4-aminoquinolines, synthetic derivatives of quinine” NCT01980745 ↗ |
| Route | Oral | “INTERVENTIONS: Oral chloroquine at 150 mg/d for 12 months beginning on postoperative day 5 or placebo.” PMID 16520474 ↗ Mar 2006 |
| Target | ATM | “activation of the protein ataxia telangiectasia mutated (ATM) using the antimalarial drug chloroquine” NCT00455325 ↗ |